Barron's Medical Journal Medical and Science Reporter reporting from JP Morgan Chase Medical Conference San Fransisco CA USA
San Francisco ( AP ) -- President Obama Legacy Will Include A Cure For Breast Cancer. In The last State Of The Union Address Given in the year 2016 Barron's Medical Journal has declared A Breast Cancer Cure is On The Eight Yard Line. The
Obama administration has watched over information technology using Genomics. Today Genomics Science at The JP Morgan Chase Medical Conference has Introduced new " Game Changing " technology from Illumina.
Illumina, the $25 billion maker of gene sequencing technology, has created a new company that's trying to invent a blood test to identify all cancers in their early stages, something that would be a tremendous help in diagnosing the illness before it is too difficult to treat effectively.
The team behind the announcement is not the first to attempt something of this nature, and previous efforts by other companies have been criticized for having too little research behind them or focusing too much on detection rather than treatment. Crucially, this blood test does not exist yet, and while scientists will be working furiously to try to make it happen, it doesn't mean they will succeed.
But this latest bet is one of the best-funded, with a number of illustrious scientists already involved — and Illumina's backing may give it a critical boost.
The new company, called Grail (as in, it's trying to achieve something considered the Holy Grail for cancer researchers) hopes to have a pan-cancer blood test by 2019, an extremely ambitious goal.
That would mean that anyone could add such a test onto their annual physical — no need for separate tests for different types of lung cancer, prostate cancer, or any other form of the illness.
Breast Cancer Patients Quality Of Life Has Just Been In Proved
Obama administration has watched over information technology using Genomics. Today Genomics Science at The JP Morgan Chase Medical Conference has Introduced new " Game Changing " technology from Illumina.
Illumina, the $25 billion maker of gene sequencing technology, has created a new company that's trying to invent a blood test to identify all cancers in their early stages, something that would be a tremendous help in diagnosing the illness before it is too difficult to treat effectively.
The team behind the announcement is not the first to attempt something of this nature, and previous efforts by other companies have been criticized for having too little research behind them or focusing too much on detection rather than treatment. Crucially, this blood test does not exist yet, and while scientists will be working furiously to try to make it happen, it doesn't mean they will succeed.
But this latest bet is one of the best-funded, with a number of illustrious scientists already involved — and Illumina's backing may give it a critical boost.
The new company, called Grail (as in, it's trying to achieve something considered the Holy Grail for cancer researchers) hopes to have a pan-cancer blood test by 2019, an extremely ambitious goal.
That would mean that anyone could add such a test onto their annual physical — no need for separate tests for different types of lung cancer, prostate cancer, or any other form of the illness.
Breast Cancer Patients Quality Of Life Has Just Been In Proved
